Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) SVP Alejandra Carvajal sold 5,598 shares of Mersana Therapeutics stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $1.96, for a total value of $10,972.08. Following the sale, the senior vice president now owns 63,716 shares in the company, valued at $124,883.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Mersana Therapeutics Stock Down 5.5 %
MRSN opened at $1.88 on Thursday. The company has a debt-to-equity ratio of 2.02, a current ratio of 2.72 and a quick ratio of 2.72. Mersana Therapeutics, Inc. has a 12 month low of $1.07 and a 12 month high of $6.28. The stock has a market capitalization of $230.04 million, a P/E ratio of -1.65 and a beta of 1.49. The business has a 50 day simple moving average of $1.68 and a 200-day simple moving average of $2.37.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $8.72 million. Mersana Therapeutics had a negative return on equity of 333.91% and a negative net margin of 349.98%. Mersana Therapeutics’s revenue for the quarter was down 78.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. On average, equities analysts anticipate that Mersana Therapeutics, Inc. will post -0.71 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on MRSN
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC purchased a new position in Mersana Therapeutics in the 2nd quarter valued at approximately $90,000. Susquehanna Fundamental Investments LLC raised its stake in shares of Mersana Therapeutics by 31.9% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 308,691 shares of the company’s stock worth $620,000 after buying an additional 74,575 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Mersana Therapeutics in the 2nd quarter worth about $508,000. Marshall Wace LLP grew its stake in Mersana Therapeutics by 358.0% in the 2nd quarter. Marshall Wace LLP now owns 176,029 shares of the company’s stock valued at $354,000 after acquiring an additional 137,596 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Mersana Therapeutics by 262.1% during the 2nd quarter. XTX Topco Ltd now owns 121,432 shares of the company’s stock valued at $244,000 after acquiring an additional 87,893 shares in the last quarter. 93.92% of the stock is owned by hedge funds and other institutional investors.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Read More
- Five stocks we like better than Mersana Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Momentum Trades for October With Ample Upside Ahead
- High Flyers: 3 Natural Gas Stocks for March 2022
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.